

## Nova Eye Establishes Share Sale Facility for Unmarketable Parcels

**Adelaide, Australia, 15 July 2021** – Nova Eye Medical Limited (ASX: EYE) (Nova Eye Medical or the Company), a medical technology company committed to advanced ophthalmic treatment technologies and devices, announced today that it is establishing an opt-out unmarketable parcel sale facility (**UMP Facility**) for shareholders who hold less than \$500 worth of fully paid ordinary shares in the Company (**Unmarketable Parcel**).

As at market close on 8 July 2021 (**Record Date**), the closing price of the Company's shares on ASX was \$0.315 and on this basis an Unmarketable Parcel has been calculated to be less than 1,588 shares. In accordance with the Company's Constitution and ASX Listing Rules, the attached letter and Share Retention Form will be sent to all shareholders holding an Unmarketable Parcel of shares as at the Record Date (**Eligible Shareholder**).

Eligible Shareholders who wish to retain their shareholding need to give the Company written notice by completing and returning the Share Retention Form by no later than 5.00pm (Adelaide time) Monday, 30 August 2021 (**Closing Date**), or acquire additional shares or merge multiple holdings in the same name such that their holdings comprise a marketable parcel prior to the Closing Date, otherwise their shares will be sold by the Company.

Shareholders wishing to take advantage of the UMP Facility and have their shares sold by the Company **do not** need to take any action. The UMP Facility will enable Eligible Shareholders to sell their shares without incurring any brokerage, or handling costs. The UMP Facility will also allow the Company to reduce the significant administrative costs involved with maintaining a large number of unmarketable parcel shareholdings on its register.

A summary of key dates in relation to the UMP Facility are as follows:

Event	Date
Unmarketable Parcel Record Date	7.00pm (Adelaide time), 8 July 2021
Despatch of Letter and Retention Form to holders of Unmarketable Parcels ( <b>Minority Members</b> )	15 July 2021
Closing Date for Receipt of Share Retention Form from Minority Member	5.00pm (Adelaide time), 30 August 2021
Unmarketable Parcels for which Share Retention Forms have not been received are available for sale under the UMP Facility	3 September 2021

Unmarketable Parcel Payment Date	As soon as practicable following settlement of all shares sold under the UMP Facility.
----------------------------------	----------------------------------------------------------------------------------------

The Company may modify these dates or suspend or terminate the UMP Facility. Any modification, suspension or termination will be notified to shareholders by way of a market announcement.

***This release dated 15 July 2021 has been authorised for lodgement to ASX by the Board of Directors of Nova Eye Medical Limited and lodged by Simon Gray, Company Secretary.***

– ENDS –

**Company**

Tom Spurling  
 Director  
 Nova Eye Medical Limited  
 W +61 417 818 658  
[tspurling@nova-eye.com](mailto:tspurling@nova-eye.com)

**Investors**

Dr. Tom Duthy  
 Investor Relations & Corporate Development  
 Nova Eye Medical Limited  
 W +61 402 493 727  
[tduthy@nova-eye.com](mailto:tduthy@nova-eye.com)

**Media**

Kate Hunt  
 Head of Marketing  
 Nova Eye Medical Limited  
 W +61 404 080 679  
[khunt@nova-eye.com](mailto:khunt@nova-eye.com)

---

**ABOUT NOVA EYE MEDICAL**

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include iTrack™ minimally invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye’s natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The Molteno3® glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe glaucoma. It also offers the benefit of a simplified and faster surgical procedure. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

For additional information about Nova Eye Medical and its technologies, please visit: [www.nova-eye.com](http://www.nova-eye.com)